SCHEMBL8016141

SCHEMBL8016141

CC(C)C(=O)c1csc(-c2ccncc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.63
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 2/20 0.49
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.46
HDAC6 Q9UBN7 3/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
IDE P14735 1/20 0.44
MAPK10 P53779 1/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGDS O60760 1/20 0.43
TLR7 Q9NYK1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12158528 0.87 HDAC1 (0.60) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL13044108 0.84 RAB9A (0.65) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL15893970 0.84 MAPK1 (0.56) HPGDLMNAMAPTALDH1A1MAPK1
SCHEMBL20646867 0.82 TLR7 (0.57) HPGDMAPTALDH1A1RAB9ANPC1
SCHEMBL8278408 0.81 HPGD (0.69) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL27768683 0.81 HPGD (0.68) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL657641 0.80 ALDH1A1 (0.70) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL15893971 0.78 ALDH1A1 (0.44) HPGDLMNAALDH1A1RAB9ANPC1
SCHEMBL4735788 0.78 HPGD (0.64) HPGDLMNAMAPTMEN1KMT2A
SCHEMBL6202834 0.78 HPGD (0.64) HPGDLMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962551-B2 Quinoxalinyl derivatives ENANTA PHARMACEUTICALS, INC. (US) 2015-02-24 US disclosed
US-20090180981-A1 QUINOXALINYL DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-20090180981-A1 QUINOXALINYL DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-07-16 US disclosed
WO-2009073719-A1 QUINOXALINYL DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090180981-A1 QUINOXALINYL DERIVATIVES SQOR, ATG4A, NQO1 HPGD 242/4885LMNA 2171/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.